Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Laboratorios Farmacéuticos Rovi is a Spanish specialty pharmaceutical company focused on contract manufacturing (CDMO services) and proprietary products, particularly low molecular weight heparins (LMWHs) for anticoagulation therapy. The company gained significant visibility through its partnership with Moderna to manufacture COVID-19 vaccines at its Granada facility, though this revenue stream has declined substantially as pandemic demand normalized. Rovi's competitive position centers on its CDMO capabilities for complex injectables, its established LMWH franchise (Bemiparin), and its ISM technology platform for long-acting injectable formulations.
Rovi generates revenue through two complementary channels: (1) fee-for-service CDMO contracts where it manufactures complex sterile injectables for pharmaceutical partners, earning margins on manufacturing expertise and regulatory compliance capabilities, and (2) sales of proprietary products where it captures full commercial margins. The Moderna partnership provided exceptional but non-recurring revenue during 2021-2023. The company's ISM (Injectable Sustained Micro-particles) technology platform creates barriers to entry through proprietary formulation expertise for long-acting injectables, enabling both licensing revenue and differentiated CDMO contracts. Pricing power in CDMO stems from regulatory barriers (EU GMP certification, FDA approval for specific products) and switching costs once manufacturing is validated.
CDMO contract announcements and renewals, particularly for high-value biologics or complex injectables that utilize Granada manufacturing capacity
Post-COVID revenue normalization trajectory as Moderna vaccine manufacturing winds down and the company transitions capacity to other products
ISM platform partnership developments and regulatory approvals for long-acting injectable formulations using Rovi's proprietary technology
Bemiparin sales trends in Spain and international market expansion, particularly in emerging markets where LMWH adoption is growing
European pharmaceutical sector M&A activity and potential strategic interest in specialty CDMO assets
Revenue concentration risk from Moderna partnership decline - the company must successfully redeploy Granada manufacturing capacity to alternative CDMO contracts or proprietary products to maintain profitability
European pharmaceutical pricing pressure and government healthcare budget constraints affecting Bemiparin reimbursement rates in Spain and other EU markets
Biosimilar and generic competition in the LMWH market as patents expire, potentially eroding Bemiparin's market position
Regulatory compliance risks inherent to pharmaceutical manufacturing - any FDA or EMA inspection findings could disrupt production and damage reputation
CDMO market competition from larger contract manufacturers (Catalent, Lonza, Thermo Fisher) with greater scale and global footprint
ISM platform adoption risk if pharmaceutical partners choose alternative long-acting injectable technologies or in-house development
Limited geographic diversification compared to global pharmaceutical companies - heavy exposure to European markets and regulatory environment
Minimal financial leverage risk given 0.20 debt-to-equity ratio and strong liquidity position
Capital allocation risk if management pursues inorganic growth through acquisitions at unfavorable valuations
Currency exposure to USD for international contracts and raw material purchases, though euro strength can benefit export competitiveness
low - Pharmaceutical demand is relatively non-cyclical as healthcare spending remains stable through economic cycles. CDMO services are driven by pharmaceutical industry R&D pipelines and regulatory approval timelines rather than GDP growth. However, discretionary healthcare spending in emerging markets (where Rovi exports Bemiparin) shows modest correlation to local economic conditions. The company's revenue decline reflects product-specific dynamics (COVID normalization) rather than macro weakness.
Rising interest rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for growth-oriented biotech/pharma stocks, particularly affecting Rovi's premium valuation (21.7x EV/EBITDA), and (2) increased financing costs for capacity expansion, though Rovi's low leverage (0.20 D/E) and strong balance sheet (3.02 current ratio) minimize this effect. European Central Bank policy affects euro-denominated financing costs and currency dynamics for international sales.
Minimal - pharmaceutical customers (large pharma companies) have strong credit profiles, and Rovi's working capital position is robust. The company is a net cash generator with positive free cash flow, not dependent on credit markets for operations.
growth - The 5.6x price-to-sales and 21.7x EV/EBITDA multiples reflect investor expectations for recovery and growth as the company transitions post-COVID. Investors are attracted to the ISM platform's long-term potential, CDMO market exposure, and Spanish mid-cap pharmaceutical story. The recent negative growth (-7.9% revenue, -19.6% net income) represents a transition period rather than structural decline, appealing to investors who believe in normalization and capacity redeployment. Limited liquidity as a smaller European stock attracts specialized healthcare investors rather than broad index funds.
moderate-to-high - As a mid-cap specialty pharmaceutical stock with concentrated revenue sources, Rovi exhibits higher volatility than large-cap diversified pharma. Stock performance is sensitive to binary events (contract announcements, regulatory approvals, partnership deals). The 0% returns across 3-month, 6-month, and 1-year periods suggest either data limitations or a period of consolidation following earlier volatility. European small/mid-cap healthcare stocks typically trade with beta above 1.0 relative to broader indices.